The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia

Transplantation

Volumn 61, Issue 10, 1996, Pages 1443-1446

  Yin, Ming ^a   Buurman, Wim A ^a   Daemen, Jan Willem H C ^a   Kootstra, Gauke ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GRAFT SURVIVAL; ISCHEMIA; KIDNEY FUNCTION; KIDNEY GRAFT; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; REPERFUSION INJURY; SURVIVAL;

ANIMALS; HEAT; IMMUNITY, CELLULAR; ISCHEMIA; ISOQUINOLINES; KIDNEY; KIDNEY CORTEX; KIDNEY TRANSPLANTATION; LUNG; MACROPHAGES; MONOCYTES; NEUTROPHILS; ORGAN PRESERVATION; PEROXIDASE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PYRIDINIUM COMPOUNDS; RATS; RATS, INBRED LEW; REPERFUSION INJURY; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 0029894190     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00004     Document Type: Article

References (26)

1. Booster MH, Wijnen EMH, Vroemen JPAM, Hooff JP van, Kootstra G. In situ perfusion of kidneys from non-heart-beating donors: proposal for a standardized protocol. Transplantation 1993; 56: 613.
2. Willinger CC, Schramek H, Pfaller K, Pfaller W. Tissue distribution of neutrophils in postischemic acute renal failure. Virchow Archiv B Cell Pathol 1992; 62: 237.
3. Schlondorff D, Neuwirth R. Platelet-activating factor and the kidney, Am J Physiol 1986; 251: F1.
4. Kubes P, Ibbotson G, Russell J, Wallace JL, Granger DN. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol 1990; 259 (gastrointest liver physiol 22): G300.
5. Bienvenu K, Russell J, Granger DN. Platelet-activating factor promotes shear rate-dependent leukocyte adhesion in postcapillary venules. J Lipid Mediat 1993; 8: 95.
6. López-Farré A, Torralbo M, López-Novoa JM. Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor. Biochem Biophys Res Commun 1988; 152: 129.
7. Yin M, Kurvers HAJM, Buurman WA, et al. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. Transplant Proc 1995; 27: 774.
8. Torras J, Bordalba JR, Seron D, et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. Transplant Int 1993; 6: 236.
9. López-Farré A, Bernabeu F, Gómez-Garré D, Cajal SRY, Braquet P, López-Novoa JM. Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats. J Pharmacol Exp Ther 1990; 253: 328.
10. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist, in endotoxin and anaphylatic shock in rodents. J Pharmacol Exp Ther 1992; 260: 748.
11. Koike K, Moore FA, Morre EE, Read RA, Carl VS, Banerjee A. Gut ischemia mediates lung injury by a xanthine oxidase-dependent neutrophil mechanism. J Surg Res 1993; 54: 469.
12. Bradley PP, Priebat DA, Christensen RD, Rothstein C. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206.
13. Griswold DE, Hillegass L, Hill DE, Sherief HT, Kopia GA. Evaluation of the effect of evan's blue and triphenyltetrazolium chloride dyes on myeloperoxidase activity in canine cardiac tissue. J Pharmacol Methods 1989; 21: 13.
14. Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990; 24: 285.
15. Persoons MCJ, Daemen MJAP, Bruning JH, Bruggeman CA. Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats: a clue to herpes virus-associated atherogenesis? Circ Res 1994; 75: 214.
16. Moore EE, Moore FA, Franciose RJ, Kim FJ, Biffl WL, Banerjee A. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma 1994; 37: 811.
17. Andreoli SP, Mallett C, Williams K, McAteer JA, Rothlein R, Doerschuk CM. Mechanisms of polymorphonuclear leukocyte mediated peritoneal mesothelial cell injury. Kidney Int 1994; 46: 1100.
18. Welbourn CRB, Goldman G, Valeri CR, Shepro D, Hechtman HB. Pathophysiology of ischemia reperfusion injury: central role of the neutrophil. Br J Surg 1991; 78: 651.
19. Biffl WL, Moore EE, Moore FA, Carl VS, Kim FJ, Franciose RJ. Interleukin-6 potentiates neutrophil priming with platelet-activating factor. Arch Surg 1994; 129: 1131.
20. Linas SL, Whittenburg D, Parsons PE, Repine JE. Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 1992; 42: 610.
21. Garcia JGN, Azghani A, Callahan KS, Johnson AR. Effect of platelet activating factor on leukocyte-endothelial cell interactions. Thromb Res 1988; 51: 83.
22. Scherf H, Nies AS, Schwertschlag U, Hughes M, Gerber JG. Hemodynamic effects of platelet activating factor in the dog kidney in vivo. Hypertension 1986; 8: 737.
23. Matsuda Y, Shibamoto T, Hayashi T Jr, et al. Renal vascular and sympathetic nerve response to hypotension induced by platelet-activating factor in anesthetized dogs. Eur J Pharmacol 1993; 250: 341.
24. Anner H, Kaufman RP, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Pulmonary leukosequestration induced by hindlimb ischemia. Ann Surg 1987; 206: 162.
25. Rabinovici R, Sofronski MD, Renz JF, et al. Platelet activating factor mediates interleukin-2-induced lung injury in the rat. J Clin Invest 1992; 89: 1669.
26. Fontes B, Moore EE, Moore FA, Koike K, Carl V, Banerjee A. PMNs primed for Superoxide release and increased CD11b expression do not sequester in normal lung. J Surg Res 1995; 58: 599.